CARB-X IS FUNDING BASILEA PHARMACEUTICA TO DEVELOP A NEW CLASS OF ANTIBIOTICS TO TREAT DRUG-RESISTANT GRAM-NEGATIVE BACTERIA
CARB-X is awarding Basilea Pharmaceutica International (SIX: BSLN), Basel, Switzerland, up to US $2.7 million to develop a novel class of antibiotics to treat Gram-negative bacterial infections. Gram-negative bacteria, often called ‘superbugs’ because they have developed resistance at an alarming pace to existing antibiotics, kill an estimated 700,000 people each year around the world.
Join the AMR Insights Ambassador Network today!
Connect to over 550 AMR professionals and students in 60 countries!